Prognostic significance of NT-proBNP levels in patients treated with empagliflozin.

IF 1.1 4区医学 Q3 UROLOGY & NEPHROLOGY

Clinical nephrology Pub Date : 2025-03-01 DOI:10.5414/CN111640

Beyza Algul Durak, Musa Ilker Durak, Naim Ata, Mahir Ülgü, Şuayip Birinci

{"title":"Prognostic significance of NT-proBNP levels in patients treated with empagliflozin.","authors":"Beyza Algul Durak, Musa Ilker Durak, Naim Ata, Mahir Ülgü, Şuayip Birinci","doi":"10.5414/CN111640","DOIUrl":null,"url":null,"abstract":"Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been added to the mainstay of treatment for chronic heart failure. Recent studies suggest that empagliflozin may also reverse cardiac remodeling in heart failure by reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. In our study, we wanted to show the decrease in NT-proBNP levels, which is an indicator of poor prognosis in heart failure, and to see if there was a decrease in the rate of renal progression in patients with HF after empagliflozin use.Materials and methods: Patients with type 2 diabetes mellitus and heart failure using empagliflozin were selected from the system and 456 patients were found. Patients were divided into two groups: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The patients were divided into two groups according to their NT-proBNP levels at the beginning of the drug and on the 90th day. The laboratory data were analyzed at the time of drug initiation and at day 90.Results: There was a statistically significant difference between baseline and day 90 HbA1C and NT-proBNP levels (p < 0.001), (p < 0.001). NT-proBNP and creatinine levels at baseline and day 90 were significantly higher in patients with HFrEF than in those with HFpEF (p < 0.001). According to the multivariate analysis, patients with HFrEF were 11.42 times more likely to have an NT-proBNP change above 300 pg/mL than patients with HFpEF (OR: 11.42, p = 0.028).Conclusion: In our study, a significant reduction in NT-proBNP and HbA1C levels was observed, while renal function was preserved.","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":" ","pages":"225-231"},"PeriodicalIF":1.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CN111640","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been added to the mainstay of treatment for chronic heart failure. Recent studies suggest that empagliflozin may also reverse cardiac remodeling in heart failure by reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. In our study, we wanted to show the decrease in NT-proBNP levels, which is an indicator of poor prognosis in heart failure, and to see if there was a decrease in the rate of renal progression in patients with HF after empagliflozin use.

Materials and methods: Patients with type 2 diabetes mellitus and heart failure using empagliflozin were selected from the system and 456 patients were found. Patients were divided into two groups: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The patients were divided into two groups according to their NT-proBNP levels at the beginning of the drug and on the 90^th day. The laboratory data were analyzed at the time of drug initiation and at day 90.

Results: There was a statistically significant difference between baseline and day 90 HbA1C and NT-proBNP levels (p < 0.001), (p < 0.001). NT-proBNP and creatinine levels at baseline and day 90 were significantly higher in patients with HFrEF than in those with HFpEF (p < 0.001). According to the multivariate analysis, patients with HFrEF were 11.42 times more likely to have an NT-proBNP change above 300 pg/mL than patients with HFpEF (OR: 11.42, p = 0.028).

Conclusion: In our study, a significant reduction in NT-proBNP and HbA1C levels was observed, while renal function was preserved.

查看原文本刊更多论文

恩格列净治疗患者NT-proBNP水平的预后意义。

背景：钠-葡萄糖共转运蛋白-2 （SGLT-2）抑制剂已被添加到慢性心力衰竭的主要治疗中。最近的研究表明，恩格列净也可能通过降低n端前b型利钠肽（NT-proBNP）水平来逆转心力衰竭时的心脏重构。在我们的研究中，我们想要显示NT-proBNP水平的降低，这是心衰预后不良的一个指标，并观察使用恩格列净后HF患者肾脏进展率是否降低。材料与方法：从系统中选取使用恩格列净的2型糖尿病合并心力衰竭患者456例。患者分为两组：保留射血分数的心力衰竭（HFpEF）和降低射血分数的心力衰竭（HFrEF）。根据用药初期和第90天NT-proBNP水平将患者分为两组。在给药时和第90天对实验室数据进行分析。结果：基线和第90天HbA1C和NT-proBNP水平差异有统计学意义（p < 0.001），（p < 0.001）。HFrEF患者在基线和第90天的NT-proBNP和肌酐水平显著高于HFpEF患者（p < 0.001）。根据多变量分析，HFrEF患者NT-proBNP变化高于300 pg/mL的可能性是HFpEF患者的11.42倍（OR: 11.42, p = 0.028）。结论：在我们的研究中，观察到NT-proBNP和HbA1C水平显著降低，而肾功能得到保留。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical nephrology 医学-泌尿学与肾脏学

CiteScore

2.10

自引率

9.10%

发文量

138

审稿时长

4-8 weeks

期刊介绍： Clinical Nephrology appears monthly and publishes manuscripts containing original material with emphasis on the following topics: prophylaxis, pathophysiology, immunology, diagnosis, therapy, experimental approaches and dialysis and transplantation.